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PPARg is a member of the nuclear receptor family for which agonist ligands have antigrowth effects.
However, clinical studies using PPARg ligands as a monotherapy failed to show a beneficial effect.
Here we have studied the effects of PPARg activation with chemotherapeutic agents in current
use for specific cancers. We observed a striking synergy between rosiglitazone and platinum-based
drugs in several different cancers both in vitro and using transplantable and chemically induced
‘‘spontaneous’’ tumor models. The effect appears to be due in part to PPARg-mediated downregu-
lation of metallothioneins, proteins that have been shown to be involved in resistance to platinum-
based therapy. These data strongly suggest combining PPARg agonists and platinum-based drugs
for the treatment of certain human cancers.INTRODUCTION
Peroxisome proliferator-activated receptor g (PPARg) is
a member of the nuclear hormone receptor superfamily
of ligand-activated transcription factors (Michalik et al.,
2004; Rosen and Spiegelman, 2001). Ligands for PPARg
include natural compounds such as fatty acids and their
derivatives and synthetic agents such as the antidiabetic
drugs rosiglitazone (Avandia) and pioglitazone (Actos)
(Forman et al., 1995; Lehmann et al., 1995). Although
a central role for PPARg has been demonstrated in the dif-
ferentiation of adipose cells, PPARg has also been shown
to regulate the growth, differentiation, and gene expres-
sion of a number of different cancer cells (Altiok et al.,
1997; Barak et al., 1999; Gupta and Dubois, 2002; Kubota
et al., 1999;Michalik et al., 2004; Rosen et al., 1999; Rosen
and Spiegelman, 2001; Sporn et al., 2001; Tontonoz et al.,
1994, 1997). Based on the antigrowth and prodifferentia-tion properties of PPARg, several clinical studies have
been performed with PPARg ligands in human cancer.
Treatment of patients with pleomorphic/myxoid round-
cell liposarcomas with troglitazone showed a significant
effect on tumor differentiation and decreased cell prolifer-
ation (Demetri et al., 1999). However, small clinical trials
involving several more common advanced epithelial ma-
lignancies showed no beneficial effect using PPARg li-
gands as a monotherapy (Burstein et al., 2003; Kulke
et al., 2002; Smith et al., 2004). Taken together, these
studies suggest that, despite their promise, the use of
PPARg ligands as a monotherapy in advanced disease
may not be beneficial.
In the context of human cancer, it is important to note
that PPARg ligands are relatively nontoxic and well toler-
ated. This is evidenced by the fact that approximately 5
million people in theUS are currently taking Actos or Avan-
dia for long-term control of type 2 diabetes. Therefore, weSIGNIFICANCE
Platinum-based drugs are used extensively in the cancer clinic. Dose-limiting toxicities and resistance remain sig-
nificant hurdles in the use of these drugs. In this manuscript we describe a powerful synergy between PPARg ag-
onists and carboplatin. PPARg agonists are already in use for the treatment of type II diabetes and have a relatively
low toxicity profile. In addition, the mechanisms appear to be mediated in part via a pathway that has been shown
to play a role in the resistance of a number of cancers to platinum-based therapy. These data suggest the use of
PPARg ligands and platinum-based drugs not only to achieve better cancer control but also for use in cancers that
have acquired resistance to platinum-based therapy.Cancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc. 395
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PPARg Synergizes with Platins in CancerFigure 1. PPARg Activation Enhances Carboplatin Growth Inhibition in A549 Lung Adenocarcinoma Cells
(A) A549 cells treated with 0.5 mM of rosiglitazone and indicated doses of carboplatin alone or in combination.
(B) A549 cells were treated with 1 mm rosiglitazone, 250 nM GW1929, or carboplatin, alone or in combination.
(C) A549 cells were treated with 0.5 mM rosiglitazone alone or in combination with 250 nM GW9662, with and without carboplatin.
(D) Interaction of rosiglitazone with different platinum-based drugs. A549 cells treated with 0.5 mM rosiglitazone, 10 mM carboplatin, 1 mM cisplatin, or
1 mM oxaliplatin alone or in combination. Cell number was determined after 7–10 days and expressed as a percent of control cells. Representative
experiments, n = 3, mean ± SD. *p < 0.05, **p < 0.01.have undertaken studies to explore the adjuvant use of
PPARg with a variety of agents that are currently in use
in the cancer clinic. We demonstrate in this manuscript
a striking synergy between PPARg and several members
of the platinum family of drugs on cultured cell growth
and tumor growth in vivo. Our data also suggest a likely
mechanism for this synergy: PPARg activation reduces
expression of multiple members of the metallothionein
gene family. These studies offer an exciting therapy to
enhance primary use of platinum-based cancer drugs, and
also suggest a method for overcoming platinum-drug
resistance of tumors.
RESULTS
PPARg and Carboplatin Synergize to Inhibit
Cell Growth
PPARg agonists are in wide use clinically for type II diabe-
tes and have a very good toxicity profile in comparison to
most anticancer drugs. To investigate the ability of PPARg396 Cancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc.agonists to modify the response to chemotherapeutic
drugs already in common use in the cancer clinic, we ex-
amined several epithelial-derived cancers in which PPARg
has been shown to have an antiproliferative effect. Low
doses of the PPARg ligand rosiglitazone were used in
combination with several different chemotherapeutic
agents. In most of the cancers examined, PPARg ligand
and the drugs used in treating those cancers failed to
demonstrate additive or synergistic effects. However,
there was a dramatic effect on a non-small-cell lung can-
cer (NSCLC) cell line when a PPARg ligand was combined
with carboplatin, a platinum-based drug used to treat lung
cancer (Figure 1A) (Cosaert and Quoix, 2002). Treatment
of the NSCLC cell line with a relatively low dose (0.5 mM)
of rosiglitazone reduced cell growth by about 10%.
When this dose of rosiglitazone was combined with
2.5 mM carboplatin, growth was reduced by 50%. En-
hanced growth inhibition by rosiglitazone was also ob-
served using 10 mM and 25 mM carboplatin. For example,
while 10 mM carboplatin alone reduced growth to about
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PPARg Synergizes with Platins in Cancer40%, the combination of rosiglitazone and 10 mM carbo-
platin reduced growth to 15%, an almost 70% reduction
in cell growth versus carboplatin alone.
PPARg-independent effects have (rarely) been ob-
served for the TZD family of PPARg agonists (Chawla
et al., 2001; Koeffler, 2003). However, to rule out
a PPARg-independent effect, A549 cells were treated
with GW1929, a high-affinity non-TZD PPARg ligand
(Henke et al., 1998). Treatment of cells with 1 mM rosiglita-
zone or 250 nM GW1929 reduced growth to about 80%
compared to control (Figure 1B). Whereas 10 mM carbo-
platin reduced growth to 55%, both GW1929 and rosigli-
tazone in combination with carboplatin reduced growth
to less than 10% compared to control cells. To further
demonstrate the PPARg-dependent synergistic effect of
rosiglitazone with carboplatin, we treated cells with the
PPARg antagonist GW9662 (Huang et al., 1999). As ex-
pected, combining rosiglitazone with carboplatin dramat-
ically increased growth inhibition compared to carboplatin
alone (Figure 1C). However, the synergistic effect was sig-
nificantly blunted in the presence of GW9662. The effect of
the combination on growth was reduced by only 45% us-
ing 2.5 mM carboplatin and rosiglitazone (compared to
80% for the combination versus carboplatin alone). These
data strengthen the argument that the synergy between
rosiglitazone and carboplatin is due to PPARg-dependent
effects.
Carboplatin is a member of the platinum family of che-
motherapy agents. Carboplatin and its parent compound,
cisplatin, are two of the most commonly used platinum
drugs for the treatment of lung cancer (Cosaert andQuoix,
2002). There are also third-generation platinum-based
drugs designed to treat cancers that have become plati-
num resistant, such as oxaliplatin, which is used to treat
other cancers (Chawla et al., 2001; Raymond et al.,
2002). To determine if the effect of PPARgwith carboplatin
was a class effect or specific for carboplatin, A549 cells
were treated with carboplatin, cisplatin, or oxaliplatin
alone and in combination with rosiglitazone. Doses of
the three platinum drugs that had roughly equipotent ef-
fects alone were used, reducing growth to about 40%–
55% (Figure 1D). Treatment of A549 cells with rosiglita-
zone had a minimal effect on its own, but the combination
with carboplatin or cisplatin reduced growth to 15% and
20%, respectively. In contrast, the combination of rosigli-
tazone and oxaliplatin did not have any additive or syner-
gistic effects on cell growth.
Non-small-cell lung cancer (NSCLC) is the most com-
mon lung cancer and is comprised of different histological
subtypes, of which adenocarcinoma is the most common
(this includes the A549 cell line). We therefore evaluated
the effect of rosiglitazone and carboplatin in additional
NSCLC cell lines. Rosiglitazone had no effect on the
growth of the H23 adenocarcinoma cell line (Figure 2A).
While 10 mMcarboplatin reduced growth to 40%, combin-
ing carboplatin with rosiglitazone reduced growth to 15%,
representing more than a 70% reduction in growth versus
carboplatin alone. In another adenocarcinoma cell line,
H1650, rosiglitazone reduced growth to 70% of controlsand carboplatin reduced growth to 40% (Figure 2B). How-
ever, the combination of rosiglitazone and carboplatin
dramatically reduced growth to 6% of controls. This rep-
resents an 85% reduction in growth versus carboplatin
alone.
We next examined the effects of rosiglitazone in combi-
nation with carboplatin in two nonadenocarcinoma
NSCLC cell lines. Rosiglitazone had no effect on growth
in the squamous cell carcinoma cell line Calu1 or the ad-
enosquamous carcinoma cell line H596 (Figures 2C and
2D). The Calu1 cells were relatively sensitive to carbopla-
tin, with 2.5 mM carboplatin alone reducing growth over
60%. However, growth was reduced an additional 50%
when rosiglitazone was added. An even greater effect
was observed with 25 mMcarboplatin where the combina-
tion reduced growth to about 1%. Similar effects were
seen in theH596 cell line using 10 mMand 25 mMcarbopla-
tin. Combining rosiglitazone with 10 and 25 mM carbopla-
tin increased growth inhibition 50%and 80%, respectively
(Figures 2C and 2D).
Carboplatin is also used as a main line therapy in the
treatment of ovarian cancer. While many patients initially
respond to carboplatin, most eventually develop resis-
tance (Cannistra, 2004). Therefore, we investigated the ef-
fect of carboplatin and rosiglitazone on two ovarian can-
cer cell lines that are considered to be relatively resistant
to platinum-drug therapy (Hagopian et al., 1999). Figures
2E and 2F show that a relatively low dose of rosiglitazone
had very little effect on the growth of the ovarian cancer
cell lines OVCA420 and OVCA429. However, combining
carboplatin with rosiglitazone dramatically enhanced
growth inhibition versus carboplatin alone. This was par-
ticularly striking for the OVCA420 cell line, where combin-
ing carboplatin with rosiglitazone reduced growth over
90%. These data demonstrate that the synergistic effect
between PPARg activation and carboplatin is observed
for cells derived from multiple cancers where platinum
drugs are used.
PPARg Agonist and Carboplatin Synergize in Colon
Cancer
To further extend these studies, we asked if rosiglitazone
could make carboplatin effective even in a cancer where it
is not used clinically. For these experiments theMoser hu-
man colon cancer cell line was treated with each agent
alone or in combination. A very low dose of rosiglitazone
(50 nM) or 2.5 mMcarboplatin alone reduced growth about
15%–20%. However, the combination of both drugs led to
a 70% reduction in cell growth compared to control cells
(See Figure S1 in the Supplemental Data available with
this article online). Therefore, combining carboplatin with
PPARg ligands reduced cell growth even in cancers where
platinum-based drugs are not commonly used.
Mechanisms of Synergy between PPARg Agonists
and Platinum Drugs
The mechanism(s) operating in this drug interaction was
studied using cell-cycle analysis and global transcriptional
profile analysis. The A549 cells were treated withCancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc. 397
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PPARg Synergizes with Platins in CancerFigure 2. Rosiglitazone and Carboplatin
Synergize to Suppress Growth in Multi-
ple Cell Types
Cells were treated with the indicated concen-
trations of carboplatin and 0.5 mM rosiglitazone
or (B) 0.2 mM rosiglitazone. (A and B) NSCLC
adenocarcinoma, (C) squamous cell carci-
noma, (D) adenosquamous cell carcinoma, (E)
OVCA420, or (F) OVCA429 ovarian epithelial
cancer cell lines were treated with 1 mM rosigli-
tazone and 10 mM carboplatin alone or in com-
bination. Cell number was determined after
7–10 days and expressed as a percent of con-
trol cells. Representative experiments, n = 3
mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.rosiglitazone or carboplatin alone or in combination for 3
days, and cell-cycle analysis was performed. Carboplatin
alone led to an increase in the fraction of cells in the G2-M
phase of the cell cycle from 5% to 12% (Figure 3A). This is
consistent with the known effects of carboplatin on the cell
cycle (Eastman, 1999). Although the low dose of rosiglita-
zone had no effect on the distribution of cells in the cell cy-
cle, combining rosiglitazone with carboplatin caused an
approximate doubling of cells in the G2-M phase com-
pared to carboplatin alone.
There is evidence that the induction of G2-M arrest by
carboplatin leads to apoptotic death (DiPaola, 2002; East-
man, 1999; Gonzalez et al., 2001). We therefore investi-
gated the effect of the drug combination treatment on ap-
optosis by analyzing several molecular markers of
apoptosis; cleavage of the poly(ADP-ribosylating) enzyme
(PARP1) and annexin V-positive cells. At the doses used,
rosiglitazone alone failed to induce significant PARP1
cleavage, and carboplatin alone led to only a small in-
crease in PARP1 cleavage (Figure 3B). However, the com-
bination of rosiglitazone and carboplatin led to significant
induction of PARP1 cleavage, suggesting increased apo-
ptotic cell death. Annexin V staining indicated that there is
a low percentage (2%) of cells undergoing apoptosis in398 Cancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc.both control and rosiglitazone-treated cells. The percent-
age of apoptotic cells increased slightly to a little over 3%
following treatment with carboplatin alone (Figure 3C).
However, the combination doubled the percentage of
apoptotic cells to 6%. These data indicate that PPARg
activation is capable of increasing carboplatin-mediated
G2-M arrest and apoptosis.
To investigate the molecular interaction between the
PPARg agonist/platinum-drug synergy, cDNA microarray
analysis was performed on the RNAs after drug treatment.
We then performed cluster analysis for changes in gene
expression, focusing on pathways associated with plati-
num-drug resistance/sensitivity. Interestingly, we ob-
served reduced expression for five members of the metal-
lothionein (MT) gene family (Figure 4A). These included
MT1G, MT1H, MT1L, MT1X, and MTII. Metallothioneins
are heavymetal-binding proteins best known for their abil-
ity to protect against heavy metal toxicity, and numerous
studies have suggested a critical role for metallothioneins
in platinum-drug resistance. Real-time PCR confirmed
that rosiglitazone reduced metallothionein gene expres-
sion by 40-70% for the individual family members
(Figure 4B). In order to demonstrate that downregulation
of metallothionein gene expression by rosiglitazone was
Cancer Cell
PPARg Synergizes with Platins in CancerFigure 3. Combination Treatment In-
creases G2-M Arrest and Apoptosis
A549 cells were treated with 0.5 mM rosiglita-
zone or 10 mMcarboplatin alone or in combina-
tion.
(A) Cell-cycle analysis was determined by PI
staining using FACS. n = 3 ± SD.
(B) Immunoblotting for cleaved PARP-1. 115
kDa, uncleaved PARP1; 85 kDa, cleaved
PARP1.
(C) Percentage of apoptotic cells as deter-
mined by annexin V-positive cells using FACS
analysis. Representative experiments, n = 3
mean ± SD. *p < 0.05, **p < 0.01.PPARg dependent, we again used the non-TZD PPARg
agonist GW1929. Figure 4C shows that GW1929 also re-
duced expression of the four metallothioneins in a similar
fashion to rosiglitazone. We next wanted to determine if
metallothionein protein levels were altered by PPARg ac-
tivation using rosiglitazone or GW1929. Since there is no
subtype-specific antibody, we used a panmetallothionein
antibody. As shown in Figure 4D, total metallothionein
protein expression was reduced by both rosiglitazone
and GW1929. This demonstrates that PPARg decreases
the mRNA expression of specific metallothioneins, which
correlates with a reduction in total metallothionein protein
expression.
Tomore fully evaluate the PPARg dependence of metal-
lothionein regulation, we treated cells with rosiglitazone
alone or in combination with the PPARg antagonistGW9662. Rosiglitazone alone reduced metallothionein
expression as expected, while GW9662 alone did not
(Figure 4E and data not shown). However, cotreatment
with GW9662 abrogated the downregulation of the metal-
lothioneins by rosiglitazone (Figure 4E). These data dem-
onstrate that not only is the synergistic effect of rosiglita-
zone and carboplatin on cell growth PPARg dependent,
but also the downregulation of metallothioneins.
To determine whether the ability of PPARg to reduce
metallothionein expression affected the interdrug syn-
ergy, a retrovirus expressing MT1H was used to elevate
the levels of this protein in the A549 cell line. Ectopic ex-
pression of MT1H raised MT1H mRNA levels almost
45-fold (Figure S2). We then treated the cells with rosigli-
tazone or carboplatin alone and in combination. As ex-
pected, the combination of carboplatin and rosiglitazoneCancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc. 399
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PPARg Synergizes with Platins in CancerFigure 4. Rosiglitazone Suppresses Several Members of the Metallothionein Gene Family
(A) Heat diagram of cluster analysis for heavy metal binding proteins frommicroarray data of RNA following treatment with rosiglitazone, carboplatin,
or a combination of the two.
(B) Real-time PCR for the expression of metallothioneins 1G, 1H, 1X, and IIA following treatment of A549 cells with 1 mM rosiglitazone for 24 hr.
(C) Real-time PCR for the expression of metallothioneins 1G, 1H, 1X, and IIA following treatment of A549 cells with 250 nM GW1929 for 24 hr.
(D) Metallothionein protein expression in A549 cells following treatment with PPARg agonists GW1929 (250 nM) or rosiglitazone (1 mM) for 24 hr.
(E) A549 cells were treated with 1 mM rosiglitazone alone or in combination with the PPARg antagonist GW9662 for 24 hr, and real-time PCR was
carried out for MT1G, MT1H, MT1X, and MTIIA. *p < 0.05 rosi + GW9662 versus rosiglitazone alone.
(F) Ectopic expression of MT1H blunts the synergistic effect of rosiglitazone and carboplatin. A549 cells stably transduced with a control or retrovirus
expressing MT1H were treated with 0.5 mM rosiglitazone or 10 mM carboplatin alone or in combination, and the cell number was determined using
a hemocytometer after 7 days. Representative experiment, n = 3 mean ± SD. *p < 0.05.caused a significant reduction in cell growth compared to
carboplatin alone in the control cells containing the empty
vector (Figure 4F). Growth was reduced almost 50% by
carboplatin alone compared to about 10% for the combi-
nation. In contrast, the synergistic effect of rosiglitazone
and carboplatin on cell growth was distinctly blunted in
cells where MT1H was expressed ectopically. In cells
overexpressing MT1H, combining carboplatin and rosigli-
tazone reduced growth to 30% compared to 60% for car-
boplatin alone. This strongly suggests that PPARg is
mediating its synergistic effects with carboplatin at least
in part via downregulation of metallothioneins.
PPARg and Carboplatin Synergize in Suppressing
Tumor Growth In Vivo
It was critical to determine if the synergistic effect between
PPARg ligands and carboplatin could be observed on tu-
mor growth in vivo. A549 tumor cells were injected subcu-
taneously into the flank of nude mice, and once tumors400 Cancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc.had formed (50–75 mm3), mice were treated with rosigli-
tazone, carboplatin, or the combination of the drugs. Pre-
vious studies have shown that, separately, rosiglitazone
and carboplatin are effective antineoplastic agents in
this type of xenograft model (Keshamouni et al., 2004;
Sirotnak et al., 2000). To investigate synergy, we first
used low doses of both rosiglitazone (5 mg/kg) and carbo-
platin (10 mg/kg). As shown in Figure 5, these doses of
carboplatin and rosiglitazone had a minimal effect on
growth of the tumors, with tumors increasing in size 11-
fold over the course of the experiment (Figure 5A). How-
ever, when rosiglitazone was combined with carboplatin,
there was a significant reduction in tumor growth, with
tumors from these mice being only one-third the size of
controls.
We then treated themice with doses of both carboplatin
(50mg/kg) and rosiglitazone (20mg/kg) at doses that have
each been shown to reduce tumor growth in vivo by each
agent alone (Keshamouni et al., 2004; Sirotnak et al.,
Cancer Cell
PPARg Synergizes with Platins in CancerFigure 5. Rosiglitazone and Carboplatin Synergize In Vivo to Reduce Tumor Growth
13 107 A549 cells were injected subcutaneously into the flank of nudemice. Once the tumor reached 50–75 mm3, treatments were initiated. (A) Con-
trol chow, chow containing 5 mg/kg/day rosiglitazone, 10 mg/kg carboplatin IP two times per week or in combination. (B) Control chow, chow con-
taining 20 mg/kg rosiglitazone/day, 50 mg/kg carboplatin IP two times per week or in combination. Tumor growth was measured two times per week.
n = 10 mice per group, mean ± SD. *p < 0.05. (C) Average TUNEL-positive cells per field from paraffin-embedded sections of animals treated with
either drug alone or in combination. n = 5–8 tumors per group, 4 fields per tumor section, mean ± SD. (D) PPARg suppresses MT gene expression
in vivo. RNAwas isolated from tumors ofmice treatedwith rosiglitazone and carboplatin and expression of the indicatedmetallothioneins determined.
n = 6–9 tumors per group, mean ± SD. *p < 0.05, **p < 0.0005.2000). Although tumor growth was reduced in mice
treated with each agent alone, tumors still increased in
size by 3-fold (Figure 5B). In striking contrast, growth of
the tumors in animals treated with the combination was
completely arrested. It is important to note that the combi-
nation did not appear to have an overall increased toxic
effect, since a difference in weights of the mice was not
observed (Figure S3). These data demonstrate that com-
bining the PPARg ligand rosiglitazone with carboplatin
dramatically reduces tumor growth in vivo.
Our in vitro data indicate that the synergistic effect be-
tween rosiglitazone and carboplatin on cell growth is in
part via increased apoptosis. We performed TUNEL stain-
ing on paraffin-embedded sections from the xenografted
tumors of mice treated with rosiglitazone and carboplatin.
Figure 5C shows that rosiglitazone and carboplatin alone
increased the number of TUNEL-positive cells compared
to sections from control-treated tumors. However, the
combination dramatically increased the number of
TUNEL-positive cells compared to either treatment alone.
We also performed an additional xenograft study using
a different cancer typewhere carboplatin is used clinically:
ovarian epithelial cancer. Following inoculation of ES2ovarian cancer cells and establishment of tumors (150
mm3), mice were treated with rosiglitazone or carboplatin
alone or in combination for 6 weeks. While rosiglitazone
and carboplatin alone did not have a significant effect on
tumor growth, there was a significant reduction in tumor
size in mice treated with the combination (Figure S4).
Tumors were roughly half the size in mice treated with
a combination of agents versus control mice or mice
treated with a single agent alone. Indeed, due to IACUC
guidelines on tumor size, many of the control and single-
drug-treated mice had to be euthanized, compared to
none of the combination-treated mice.
We next extracted RNA from the A549 lung cancer-
derived tumors that grew in control mice or mice treated
with the low doses of carboplatin, rosiglitazone, or both
drugs together and examined changes in metallothionein
gene expression. As shown in Figure 5D, rosiglitazone
alone significantly lowered MT1H and IIA gene expression
in tumorsby 70%–80%compared to control tumors.MT1G
andMT1X gene expression was reduced as well, although
it was not statistically significant. Interestingly, expression
of all four metallothioneins was elevated 2- to 3-fold in tu-
mors from animals treated with carboplatin. Importantly,Cancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc. 401
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PPARg Synergizes with Platins in Cancerin the animals receiving carboplatin and rosiglitazone, the
induction of MT1H, MT1X, and MTIIA by carboplatin was
blunted significantly (MT1G expression was also reduced,
but it was not statistically significant). Expression of all
three metallothioneins from tumors of mice treated with
both rosiglitazone and carboplatin was down over 70%
compared to animals receiving carboplatin alone. These
data demonstrate that the ability of rosiglitazone to syner-
gize with carboplatin in vivo is associated with a reduction
in metallothionein expression in the tumors themselves.
Xenograft experiments are useful as an in vivo model for
tumor growth. However, they are limited in that they do not
truly represent a tumor that develops ‘‘spontaneously’’
such as is the case in the human condition. We used the
colon-specific carcinogen azoxymethane to induce spon-
taneous colonic tumors in mice. Mice were treated with
AOM once a week for 6 weeks. We waited an additional
12 weeks to begin treating mice in order to establish car-
cinogenesis. Mice were treated with rosiglitazone, carbo-
platin, or a combination of the two for 6 weeks. We then
examined mice for incidence of polyp formation and mul-
tiplicity of tumors. As shown in Figure 6A, the incidence of
polyp formation was reduced in mice treated with rosigli-
tazone and carboplatin compared to control or single
treatments. Only 25% of the combination-treated animals
developed polyps compared to almost half or more of the
rosiglitazone or carboplatin treatments alone. The number
of polyps per mouse was also down more than 75% com-
pared to single treatment or controls (Figure 6B). These
data demonstrate the effect of carboplatin and rosiglita-
zone in different cancer types and against ‘‘spontaneous’’
tumor formation.
DISCUSSION
Numerous reports over the last 10 years have docu-
mented the antiproliferative effects of PPARg ligands
(Gupta and Dubois, 2002; Michalik et al., 2004; Rosen
and Spiegelman, 2001; Sporn et al., 2001). Genetic stud-
ies have also indicated that PPARg functions as a tumor
suppressor in a variety of tissues, including breast, pros-
tate, and colon (Girnun et al., 2002; Mueller et al., 2000;
Nicol et al., 2004; Sabatino et al., 2005; Sarraf et al.,
1999). Together, these studies offered the potential of
cancer control with agonist agents that are generally
well tolerated and relatively nontoxic compared to current
chemotherapy. Unfortunately, with the exception of
a small trial on liposarcomas, clinical trials have indicated
that PPARg ligandsmay not be useful as amonotherapy in
advanced disease (Burstein et al., 2003; Demetri et al.,
1999; Kulke et al., 2002; Smith et al., 2004). Because cur-
rent cancer therapy invariably utilizes a combination of
chemotherapeutic drugs, we investigated whether PPARg
ligands could be used as an adjuvant therapy with agents
already in use for specific cancers. We describe here that
agonist activation of PPARg dramatically increases the
growth-inhibitory effect of the platinum-based drugs cis-
platin and carboplatin in several different types of cancers
where platinum drugs are currently used. For example, in402 Cancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc.lung adenocarcinoma cells, a low concentration of rosigli-
tazone increased the efficacy of carboplatin 4-fold. Nota-
bly, we observed a similar synergistic effect on growth
inhibition between carboplatin and rosiglitazone in a num-
ber of different non-small-cell lung cancer subtypes and
ovarian cancer cells. Our data also demonstrate that
the synergistic effect of rosiglitazone and carboplatin on
cell growth may very well be applicable to cancers where
carboplatin is not currently in clinical use, such as colon
cancer.
Most importantly, the synergistic interaction between
rosiglitazone and carboplatin could also be observed on
tumor growth in vivo with transplantable human cancers.
Initially, we used doses of rosiglitazone and carboplatin
that were five and ten times lower, respectively, than
what has been published as being inhibitory toward tumor
growth in order to demonstrate synergy for particular lung
adenocarcinoma cell line. Indeed, using these low doses,
Figure 6. Rosiglitazone and Carboplatin Synergize In Vivo in
a Spontaneous Tumor Model
Mice were treated with 10 mg/kg AOM once a week for 6 weeks. Fol-
lowing an additional 12 weeks, mice were treated as described in the
Experimental Procedures for 6 weeks. Mice were then euthanized and
examined for tumor incidence (A) or number of polyps per mouse (B).
n = 8–9 mice per group, mean ± SD. *p < 0.05 versus control, rosigli-
tazone alone, or carboplatin alone.
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PPARg Synergizes with Platins in Cancerwe saw no effect of either drug on its own, but a dramatic
growth-inhibitory effect on tumors was observed when
carboplatin and rosiglitazone were combined. This effect
was also seen at doses where the individual drugs had
some mild tumor-inhibitory effects; the combination at
these higher concentrations essentially led to stasis if
not tumor shrinkage, which appears to be accompanied
by increased apoptosis. Using these higher doses on an
ovarian cancer cell line, we observed no effect of either
drug alone, but a significant reduction in tumor growth
by the combination of rosiglitazone and carboplatin. Im-
portantly, the synergistic effect of the combination was
observed using a chemically induced ‘‘spontaneously’’
growing tumor. Tumor incidence andmultiplicity were sig-
nificantly lower than control or either rosiglitazone or car-
boplatin alone. In addition, since the effect was observed
in a cancer type (colon) where carboplatin is not typically
used, it strengthens the possibility of adding a new
chemotherapeutic regimen to the treatment of colorectal
cancer.
The combination of carboplatin and the PPARg agonist
did not appear to increase systemic toxicity since the
body weights and overall appearance of mice being given
the combination of drugs were not different from controls
or the mice receiving only one drug. In addition, a recent
study showed that PPARg ligands are actually protective
against platinum-drug toxicity in mice (Lee et al., 2006).
Thus, our finding that PPARg activation dramatically in-
creases the efficacy of carboplatin, potentially causing
tumor stasis or even tumor shrinkage, could represent
a significant advance in chemotherapy.
Platinum-based drugs are known to induce G2-M
phase arrest, followed by apoptosis (DiPaola, 2002; East-
man, 1999; Gonzalez et al., 2001). Many studies have
shown that the growth-inhibitory effects of PPARg ligands
occur via effects on cell-cycle arrest, as well as through in-
creased apoptosis (Altiok et al., 1997; Chang and Szabo,
2000; Keshamouni et al., 2004; Koeffler, 2003). These pre-
vious studies were performed using doses of rosiglitazone
(or equivalent compounds) that were five to ten times
greater than the doses we used. Using low doses of rosi-
glitazone, we did not observe effects on cell cycle or apo-
ptosis. However, these low concentrations of rosiglita-
zone significantly increased the cell-cycle arrest and
apoptosis induced by carboplatin. Furthermore, TUNEL
staining of sections from tumors of mice following treat-
ment with either drug alone or drug combination demon-
strated increased apoptosis as a result of the combination
treatment. Therefore, these studies demonstrate a dual
effect of combining rosiglitazone with rosiglitazone:
decreased proliferation and increased apoptosis. In addi-
tion to direct effects on tumor cell apoptosis and cell-cycle
arrest, the effects of rosiglitazone in vivo have also been
attributed to certain antiangiogenic properties of PPARg
ligands; such additional effects on angiogenesis in vivo
cannot be ruled out here (Panigrahy et al., 2002).
The mechanism(s) of how platinum-based drugs exert
their cytotoxic effects has been extensively studied.
Many pathways have been studied that are believed toplay a role in the resistance to platinum-based drugs
(Akiyama et al., 1999; Chu, 1994; Perez, 1998). These
pathways can be classified into two functional categories.
One is the response to and repair of platinum-adducted
DNA and the other is limiting/inactivating platinum-drug
activity. Our data demonstrate that PPARg suppresses
the expression of several members of the metallothionein
family, a family of small (60 amino acids) zinc- and cys-
teine-rich proteins that are best characterized by their
ability to bind to and detoxify heavy metals (Coyle et al.,
2002). Many studies have shown that metallothioneins
play a role in the resistance of certain cancers to plati-
num-based drugs (Akiyama et al., 1999; Chu, 1994; Perez,
1998). This is highlighted by the observation that metallo-
thionein expression is elevated in many platinum-resistant
cell lines and tumors (Hishikawa et al., 1997). In addition,
chemically or genetically increasing metallothionein levels
has been shown to induce resistance to platinum drugs
(Andrews et al., 1987; Cheng et al., 2006; Hishikawa
et al., 1997; Kasahara et al., 1991; Kelley et al., 1988).
Therefore, the ability of rosiglitazone to reduce the expres-
sion of multiple members of the metallothionein family
shown here probably renders cells more sensitive to plat-
inum therapy. We observed increased metallothionein
expression in tumors of mice following treatment with car-
boplatin, which was reduced when combined with rosigli-
tazone. This effect correlated with enhanced growth
suppression of these tumors; ectopic expression of amet-
allothionein reduced the synergy between the rosiglita-
zone and carboplatin in cultured cells. These data to-
gether suggest strongly that the ability of PPARg ligands
to suppress metallothionein levels both in vitro and
in vivo may, in part, explain the synergy observed with
carboplatin.
Although PPARg is generally considered a transcription
factor that increases gene expression, PPARg has also
been shown to repress gene expression. Studies by
a number of other labs have demonstrated that PPARg
can repress gene expression via transrepression of AP1
(Delerive et al., 2001; Ricote et al., 1998). Activation of
AP1 is antiapoptotic and associated with increased prolif-
eration (Eferl and Wagner, 2003; Karin et al., 2002). In ad-
dition, metallothioneins have been shown to be regulated
by AP1 (Abate et al., 1990; Lee et al., 1987). Therefore, the
repression of metallothioneins we observe by PPARg ac-
tivation may be mediated via transrepression of AP1.
Though these studies support the suppression ofmetal-
lothionein expression as a plausible mechanism by which
rosiglitazone may augment platinum action, there may
well be other important mechanisms of synergy. Indeed,
the fact that adding back MT1H partially blunts the syn-
ergy suggests that other pathways may be involved. The
partial effect may reflect the fact that we are ectopically
expressing only MT1H, whereas rosiglitazone represses
several additional metallothionein family members. Other
platinum resistance pathways such as the DNA repair
gene ERCC1, the DNA-binding geneHMGB1, or the gluta-
thione pathway may also be involved (Akiyama et al.,
1999; Chu, 1994; Perez, 1998). We examined our DNACancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc. 403
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by rosiglitazone. However, significant changes in expres-
sion were not observed (Figure S1). We are currently ex-
ploring additional members of the metallothionein family
and other resistance pathways to more fully explain the
synergistic effect.
The ability of PPARg activation to synergize with plati-
num-based drugs may be important for the treatment of
cancers, where they are used as standard therapy. This in-
cludes two of the cancers we examined in our studies,
lung and ovarian cancer. Lung cancer is the third most
commonmalignancy in the United States, behind prostate
and breast cancer, with over 170,000 cases diagnosed
each year (of which almost 90%are NSCLC). Despite mul-
timodality therapies, last year more than 160,000 deaths
were reported in the United States alone (ACS, 2006).
Ovarian cancer is the second most common gynecologi-
cal cancer, with over 20,000 cases diagnosed each year,
resulting in over 15,000 deaths in the United States each
year (ACS, 2006). While most women with ovarian cancer
initially respond to platinum-drug therapy, many tumors
eventually develop resistance (Cannistra, 2004). Therefore
the ability to increase the effectiveness of platinum drugs,
as well as the ability to overcome resistance, would repre-
sent a significant advance in the treatment of these can-
cers. In addition, dose-limiting toxicities often prevent
the use of platinum drugs for other cancers. While there
are some conflicts regarding the antigrowth properties of
PPARg agonists and even some rare reports of increased
tumorigenesis by PPARg agonists in murine models of
cancer, the vast majority of data indicate that PPARg is
antineoplastic (Koeffler, 2003; Lefebvre et al., 1998;
Saez et al., 1998; Sarraf et al., 1998). Therefore, while cau-
tion should be used with PPARg agonists, our data
strongly suggest that combining PPARg ligands with car-
boplatin may enable the expansion of platinum-based
drugs into cancers where they are not currently used.
EXPERIMENTAL PROCEDURES
Cell Culture
H23, H1600, Calu1, and H596 NSCLC cell lines were obtained from
ATCC. A549 NSCLC, OVCA 420, OVCA429, and ES2 ovarian cancer
cell lines were kind gifts from Drs. Barrett Rollins and Ronald Drapkin
(DFCI). Moser human colon cancer cells have been described previ-
ously (Sarraf et al., 1998). Rosiglitazone, GW1929, and GW9662
were obtained from ALEXIS Biochemicals. Carboplatin, cisplatin, and
oxaliplatin were obtained fromSigma-Aldrich. Cells weremaintained in
DMEMsupplementedwith 10%FBS and penicillin/streptomycin. Cells
were seeded at a density of 1000 to 10,000 cells/well in 6-well plates
and treatedwith the indicated drugs as described in the figure legends.
Cell number was determined using a hemocytometer.
Cell Cycle and Analysis of Apoptosis
Cell-cycle analysis, PARP1 cleavage, and annexin V staining were per-
formed following treatment as indicated. Propidium iodide staining
was used for cell-cycle analysis. Annexin V staining was performed ac-
cording to manufacturer’s protocol (BD Biosciences). FACS analysis
for cell-cycle and annexin V staining was performed by the Dana-
Farber Cancer Institute’s Flow Cytometry Core. For immunoblotting,
proteins from control and treated cells were separated by PAGE and
transferred to nitrocellulose as previously described (Drori et al.,404 Cancer Cell 11, 395–406, May 2007 ª2007 Elsevier Inc.2005). PARP1 antibody recognizing uncleaved and cleaved PARP1
was used at 1:2000 (BD Bioscience). Paraffin embedding, sectioning,
and TUNEL staining of tumors were performed by the Dana-Farber/
Harvard Cancer Center Rodent Histopathology Core.
RNA Isolation and Real-Time PCR/Protein Analysis
of Metallothionein Expression
RNAwas isolated from cells and tissues using Trizol reagent according
to the manufacturer’s protocol (Invitrogen). cDNA was synthesized us-
ing iScript reverse transcriptase reagent from 1 mg of total RNA (Bio-
Rad). For real-time PCR using Sybr-Green, the following primers
were used: MT1G, forward, CTCCTGCAAGTGCAAAGAGTGCAA, re-
verse, ATTTGTACTTGGGAGCAGGGCTGT; MT1H, forward, AGTCT
CACCTCGGCTTGCAATGGA, reverse, GCTCTTCTTGCAGGAGGTG
CATTT; and MT1X, forward, TCTGCAAAGGGACGTCAGACAAGT, re-
verse, TGTAGCAAACGGGTCAGGGTTGTA, and 18S as previously
described (Drori et al., 2005). Taqman PCR was performed using
Applied Biosystems Assays on Demand for MTIIA. Real-time PCR re-
actions were carried as previously described on an ABI 7300 system
(Applied Biosystems).
Following treatment with PPARg agonists, cells were harvested and
proteins were separated and transferred to nitrocellulose as previously
described (Drori et al., 2005). A panmetallothionein antibody (Abcam)
was used at 1:750 or b-actin antibody (1:5000) in TBST-5% milk over-
night, followed by HRP-conjugated anti-mouse secondary antibody
(Jackson Immuno) at 1:15000. Membranes were developed by chem-
iluminescence (Pierce, Supersignal West Pico).
Microarray Analysis
A549 cells were treated for 24 hr with vehicle control, or 0.5 mM rosigli-
tazone, 10 mM carboplatin alone, or in combination. Total RNA was
isolated using an RNeasy Mini Kit (Qiagen Inc.) and used for global
expression analysis. Affymetrix array hybridization and scanning
were performed by the Core Facility at Dana-Farber Cancer Institute
using human genome U133A chip (Affymetrix). Array data were ana-
lyzed with a d-CHIP array analysis program (Li and Wong, 2001). Array
data are deposited in the Gene Expression Omnibus (GEO) repository.
Xenograft Studies
Male nude mice were obtained from Taconic Farms. Eight- to ten-
week-old mice were inoculated subcutaneously into the right flank
with 1 3 107 A549 or ES2 cells in media. Tumors were measured
weekly with calipers in two dimensions, and tumor volume was calcu-
lated using the formula V = (P*length) 3 (width2)/6. Treatments were
initiated when tumors reached 50–75 mm3 using 8 to 12 mice per
group. For the low-dose experiment, mice were given chow containing
5 mg/kg rosiglitazone per day, 10 mg/kg carboplatin by intraperitoneal
injection two times per week, alone or in combination. For the experi-
ment with higher dose of drugs and for the ES2 cells, mice were given
chow containing 20mg/kg rosiglitazone per day, 50mg/kg carboplatin
by intraperitoneal injection two times per week, alone or in combina-
tion. Control mice were given control chow or injected with saline. All
studies were conducted in compliance with the Dana-Farber Cancer
Institute IACUC guidelines. Once tumors reached IACUC guidelines,
mice were euthanized.
Colon Carcinogenesis Studies
Twelve-week-old mice were injected IP once a week for 6 weeks with
10 mg/kg azoxymethane. Mice were followed out for 12 weeks, after
which timemicewithmicewere given control chow or chow containing
20 mg/kg rosiglitazone per day, 50 mg/kg carboplatin by intraperito-
neal injection two times per week, alone or in combination. After 6
weeks, mice were euthanized, and colons were removed and flushed
with PBS, cut longitudinally, and fixed in 10% buffered formalin
(Fisher). Colons were stained with methylene blue, and polyps were
counted blindly under a dissecting microscope.
Cancer Cell
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MT1H expression clone was obtained from ATCC. MT1H was subcl-
oned into the pMSCV-neo-retroviral vector (BD Bioscience). Retrovi-
rus expressing MT1H was generated as previously described. A549
cells were infected with control retrovirus or retrovirus expressing
MT1H, and cells were selected with G418. Expression of MT1H was
determined by real-time PCR as described above. Control and
MT1H-overexpressing cells were treated as indicated.
Microarray Data
The microarray data set has been deposited in the Gene Expression
Omnibus repository (http://www.ncbi.nlm.nih.gov/geo/), accession
no. GSE7035.
Supplemental Data
The Supplemental Data include four supplemental figures and one
supplemental table and can be found with this article online at http://
www.cancercell.org/cgi/content/full/11/5/395/DC1/.
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